SYDNEY, AUSTRALIA--(Marketwire - Jan 28, 2013) - Prima BioMed Ltd (
The presentation will be a live audio webcast and may be accessed by visiting Prima BioMed's website at http://www.primabiomed.com.au/investor/presentations.php. A replay of the webcast will be available for 90 days following the presentation.
About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
- Investment & Company Information